# GPN Vaccines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gpn-vaccines

- Industry: Biotechnology
- Headquarters: Adelaide, Australia
- Website: www.gpnvaccines.com/
- Total disclosed funding: $18M
- Latest round: Series B (Jun 7, 2024)
- Investors on record: 3

## About

Founded in 2017 and based in Adelaide, Australia, GPN Vaccines Ltd. is a biotechnology company developing a next-generation vaccine to combat Streptococcus pneumoniae, a leading cause of pneumonia, sepsis, and other illnesses. In June 2024, GPN Vaccines Ltd. raised USD 18 million in Series B funding co-led by investors Forepont Capital and Kern Capital, with participation from individual investors. As of June 2024, the company is led by CEO Tim Hirst.
 
GPN Vaccines' primary product is Gamma-PN, a whole-cell vaccine designed to offer protection against all S. pneumoniae serotypes, bacteremia, and meningitis, as well as otitis media (middle ear infections). The company also offers Pfizer's Prevnar-20 to target a limited number of serotypes. The company's streamlined manufacturing process, leveraging advanced microbial fermentation and irradiation techniques, promises cost-effectiveness and scalability. As of 2023, GPN Vaccines is conducting clinical trials to evaluate the safety, tolerability, and immunogenicity of Gamma-PNTM in comparison to Prevnar 13 and Pneumovax 23.
 
The company will use the funding to bring innovative vaccines to market and improve global health outcomes.

## Funding rounds

- Series B, Jun 7, 2024, $18M — Kern Capital, Forepont Capital Partners
- Series A, Jun 1, 2022 — Shearwater Capital

## Investors

- Shearwater Capital — Series A
- Kern Capital (https://capitalatlas.ai/funds/kern-capital) — Series B
- Forepont Capital Partners (https://capitalatlas.ai/funds/forepont-capital-partners) — Series B